Eli Lilly To Buy Dice Therapeutics For $2.4 Billion!

On Tuesday, Eli Lilly announced a $2.4 billion deal to buy Dice Therapeutics to expand its therapy range for immune-related disorders.

Eli Lilly will pay $48 per share in cash to acquire Dice, reflecting a 40% premium over the company’s Friday closing price. The deal is scheduled to be completed in the third quarter of this year. Jonathan Clark also shared the news and some stocks statistics through Twitter.

You can see his Tweet below:

Eli Lilly’s stock price increased by over 1% in early morning trade. The share price of Dice Therapeutics increased by more than 37% to slightly under the purchase price.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” In a news release, Eli Lilly executive vice president Patrik Jonsson stated

Check out The following posts if you like to stay updated about your favorite celebrity news:

What Does The “Dice” Do?

Dice is a biotech business that develops new oral therapeutic drugs for autoimmune diseases, which happen when a person’s immune system attacks their own cells instead of protecting them.

Autoimmune diseases can cause many symptoms, such as pain, tiredness, dizziness, sadness, and rashes. Autoimmune diseases include lupus, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, among many others.

The lead drug from Dice is in the middle of a study for psoriasis, a skin disease linked to the immune system. Eli Lilly’s resistant drug collection includes Taltz, used to treat plaque psoriasis, and Olumiant, used to treat rheumatoid arthritis.

Last year, Taltz made $2.48 billion in sales, while Olumiant made $830,5 million.

Eli Lilly To Buy Dice Therapeutics

We’re always adding new content, so be sure to bookmark Trending-news.org to stay up-to-date on the latest news and information

About John King

I've loved writing and learning about things ever since I was a little boy. I love my job as an author for a news company in Chicago, where I live. I've always wanted to help people learn about and keep up with the latest news. I'm very passionate about what I do, and I'm sure that hard work always pays off. I really like what I do, and I'm lucky that I can call it my job. I usually spend my free time reading or hanging out with my family and friends.

Leave a Comment